The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-14 and is reviewed periodically as new material appears.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
The European Bioinformatics Institute (EMBL-EBI) is an intergovernmental organization (IGO) which, as part of the European Molecular Biology Laboratory (EMBL) family, focuses on research and services in bioinformatics. It is located on the Wellcome Genome Campus in Hinxton near Cambridge, and employs over 600 full-time equivalent (FTE) staff. Further, the EMBL-EBI hosts training programs that teach scientists the fundamentals of the work with biological data and promote the plethora of bioinformatic tools available for their research, both EMBL-EBI-based and not so. One of the roles of the EMBL-EBI is to index and maintain biological data in a set of databases, including Ensembl (housing whole genome sequence data), UniProt (protein sequence and annotation database) and Protein Data Bank (protein and nucleic acid tertiary structure database). A variety of online services and tools is provided, such as Basic Local Alignment Search Tool (BLAST) or Clustal Omega sequence alignment tool, enabling further data analysis.
== Oxygen-15 == Oxygen-15 (half-life 122.27 seconds) is the most stable radioisotope of oxygen, decaying by positron emission to nitrogen-15. It is thus the isotope of oxygen used in positron emission tomography (PET). It can be used in, among other things, water for PET myocardial perfusion imaging and for brain imaging. It is produced for this application through deuteron bombardment of nitrogen-14 using a cyclotron.
== Adverse effects == In individuals already taking sulphonylureas, use of DPP-4-class medications concurrently increases their risk for low blood sugar events relative to those on sulphonylureas alone. Adverse effects include nasopharyngitis, headache, nausea, heart failure, hypersensitivity, and skin reactions. In late August 2015, the US FDA issued a warning that drugs like sitagliptin, saxagliptin, linagliptin, alogliptin, and other DPP-4 inhibitors could cause joint pain that can be severe and disabling. However, studies assessing risk of rheumatoid arthritis among DPP-4 inhibitor users have been inconclusive. A 2014 review found that the use of saxagliptin and alogliptin increased individuals' risk of developing heart failure, leading the FDA to add warnings to the labels of these drugs in 2016. A 2018 meta-analysis indicated that the use of DPP-4 inhibitors was associated with a 58% increased risk of developing acute pancreatitis compared to placebo or no treatment. Additionally, a 2018 observational study suggested an elevated risk of developing inflammatory bowel disease, specifically ulcerative colitis, which peaked after three to four years of use and decreased after more than four years. Finally, a 2020 Cochrane systematic review found insufficient evidence to suggest that metformin monotherapy reduced all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, or end-stage renal disease when compared to DPP-4 inhibitors for the treatment of type 2 diabetes.
Seizures of coca paste and cocaine and destruction of drug laboratories had steadily increased since President Morales took office, and coca cultivation was down 13% in 2011 alone. Analysts such as Kathryn Ledebur and Colletta Youngers indicate that these successes had emerged from effective coca monitoring, increased economic development, and "social control". Such improvements in Bolivia's narcotics situation had reportedly drawn attention and led to a slight diplomatic thaw with the United States; the two countries are expected to swap ambassadors.
=== Early Hospitals (1823-1869) === Also in 1821, Drake brought a proposal to the Ohio legislature, which approved a hospital and asylum for Cincinnati with the medical department operated by the faculty of the Medical College of Ohio. The hospital, the Commercial Hospital and Lunatic Asylum opened in 1823 at the present-day corner of 12th and Elm as a three-story brick facility that also served as an infirmary, poorhouse, and orphanage, housing roughly 250. An annex for the asylum was finished in 1827. By 1861, the hospital was officially recognized as the Commercial Hospital of Cincinnati. By 1865, the building was ill-equipped to handle the demands prompting the building of a new hospital on the existing site in 1869. This hospital was named the Cincinnati Hospital. In 1915, a new structure was built by the city and the hospital was renamed Cincinnati General Hospital. In honor of the late Dr. Christian R. Holmes, Holmes Hospital was officially opened and dedicated in 1929. Holmes Hospital was a private facility in connection with Cincinnati General Hospital where doctors from the General Hospital and College of Medicine could see their private patients. It gradually transitioned into what is now part of UC Health.
Sources: en.wikipedia.org
Simulating the systemic environment in tectonic fault zones within the Earth's crust, pressure cycling forms vesicles periodically, as well as random peptide chains which are selected for ability to integrate into the vesicle membrane. Further selection of vesicles for stability could lead to functional peptide structures, increasing vesicle survival rate.
Scientific evidence of the pernicious nature of opium use was largely undocumented in the 1890s, when Protestant missionaries in China decided to strengthen their opposition to the trade by compiling data which would demonstrate the harm the drug did. Faced with the problem that many Chinese associated Christianity with opium, partly due to the arrival of early Protestant missionaries on opium clippers, at the 1890 Shanghai Missionary Conference, they agreed to establish the Permanent Committee for the Promotion of Anti-Opium Societies in an attempt to overcome this problem and to arouse public opinion against the opium trade. The members of the committee were John Glasgow Kerr, MD, American Presbyterian Mission in Guangzhou (Canton); B.C. Atterbury, MD, American Presbyterian Mission in Beijing (Peking); Archdeacon Arthur E. Moule, Church Missionary Society in Shanghai; Henry Whitney, MD, American Board of Commissioners for foreign Missions in Fuzhou; the Rev. Samuel Clarke, China Inland Mission in Guiyang; the Rev. Arthur Gostick Shorrock, English Baptist Mission in Taiyuan; and the Rev. Griffith John, London Mission Society in Hankou. These missionaries were generally outraged over the British government's Royal Commission on Opium visiting India but not China. Accordingly, the missionaries first organized the Anti-Opium League in China among their colleagues in every mission station in China. American missionary Hampden Coit DuBose acted as first president.
== History == Phase III trials evaluated the efficacy of luspatercept for the treatment of anemia in the hematological disorders beta thalassemia and myelodysplastic syndromes. It was developed by Acceleron Pharma in collaboration with Celgene. The U.S. Food and Drug Administration (FDA) granted approval for luspatercept–aamt in November 2019, for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. Luspatercept was approved for medical use in the European Union in June 2020. The U.S. Food and Drug Administration (FDA) awarded orphan drug status in 2013, and fast track designation in 2015.
==== Ultrastructure and function ==== The serotonin nuclei may also be divided into two main groups, the rostral and caudal containing three and four nuclei respectively. The rostral group consists of the caudal linear nuclei (B8), the dorsal raphe nuclei (B6 and B7) and the median raphe nuclei (B5, B8 and B9), that project into multiple cortical and subcortical structures. The caudal group consists of the nucleus raphe magnus (B3), raphe obscurus nucleus (B2), raphe pallidus nucleus (B1), and lateral medullary reticular formation, that project into the brainstem. The serotonergic pathway is involved in sensorimotor function, with pathways projecting both into cortical (dorsal and median raphe nuclei), subcortical, and spinal areas involved in motor activity. Pharmacological manipulation suggests that serotonergic activity increases with motor activity while firing rates of serotonergic neurons increase with intense visual stimuli. Animal models suggest that kainate signaling negatively regulates serotonin actions in the retina, with possible implications for the control of the visual system. The descending projections form a pathway that inhibits pain called the "descending inhibitory pathway" that may be relevant to a disorder such as fibromyalgia, migraine, and other pain disorders, and the efficacy of antidepressants in them. Serotonergic projections from the caudal nuclei are involved in regulating mood and emotion, and hypo- or hyper-serotonergic states may be involved in depression and sickness behavior.
=== Department stores === To manage its mail order business the department store Sears built "massive warehouses, like its central facility in Chicago, in which messages to various departments and assembly workers were sent through pneumatic tubes". Many other department stores had pneumatic tube systems in the 20th century, such as Jacksons of Reading and Myer in Melbourne, Australia. The National Library of Australia's building (opened 1968), incorporates a pneumatic tube system for sending book requests from the reading rooms to the book stacks. The system is no longer used, but remains partially operational, and is demonstrated on behind the scenes tours.
Sources: en.wikipedia.org
== Legality == Nicomorphine is regulated in much the same fashion as morphine worldwide but is a Schedule I controlled substance in the United States and was never introduced there. Nicomorphine may appear on rare occasions on the European black market and other channels for unsupervised opioid users. It can be produced as part of a mixture of salts and derivatives of morphine by end users by means of treating morphine with nicotinic anhydride or related chemicals in an analogue of the heroin homebake process. CAS number of hydrochloride: 35055-78-8 US DEA ACSCN: 9312 Free base conversion ratios of salts: Nicomorphine Hydrochloride: 0.93
Gateway Distriparks Limited is an Indian logistics company based in Mumbai with three business verticals: container freight stations (CFS), inland container depots (ICD) with rail movement and cold chain storage and logistics. The company was founded in April 1994 and originally promoted by Newsprint Trading & Sales Corporation (NTSC), CWT Distribution Limited, NUR Investment and Trading Pvt. Ltd., and Intercontinental Forest Products Pte. Ltd. (IFP) as a joint venture company to conduct the business of warehousing, container freight stations and all related activities. As of November 2015, Prism International Private Limited (same group as NTSC) is the sole promoter of the company.
=== Pharmacodynamics === The mechanistic underpinnings of bemethyl's effects are not well understood, but some evidence implicate alterations in protein synthesis and glucose metabolism, in addition to antioxidant activity, as relevant mechanisms of action.
68A Biomedical Equipment Specialist 68B Orthopedic Specialist 68C Practical Nursing Specialist-(LPN/LVN) 68D Operating Room Specialist 68E Dental Specialist 68F Physical Therapy Specialist 68G Patient Administration Specialist (formerly 71G) 68H Optical Laboratory Specialist 68J Medical Logistics Specialist 68K Medical Laboratory Specialist 68L Occupational Therapy Specialist 68M Nutrition Care Specialist 68N Cardiovascular Specialist ( Discontinued) 68P Radiology Specialist 68Q Pharmacy Specialist 68R Veterinary Food Inspection Specialist 68S Preventive Medicine Specialist 68T Animal Care Specialist 68U Ear, Nose, and Throat (ENT) Specialist (Discontinued) 68V Respiratory Specialist 68W Combat Medic Specialist 68X Behavioral Health Specialist 68Y Eye Specialist 68Z Chief Medical NCO
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.